Takeda Pharmaceutical
314 hedge funds and large institutions have $1.24B invested in Takeda Pharmaceutical in 2023 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 111 increasing their positions, 92 reducing their positions, and 29 closing their positions.
967% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $4.14M
34% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 29
21% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 92
1% more funds holding
Funds holding: 311 → 314 (+3)
0.12% less ownership
Funds ownership: 2.7% → 2.59% (-0.12%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
34% less capital inflows, than outflows
Capital inflows: $101M | Capital outflows: $153M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$21M |
| 2 |
Millennium Management
New York
|
+$10.5M |
| 3 |
Morgan Stanley
New York
|
+$7.05M |
| 4 |
LMR Partners
London,
United Kingdom
|
+$5.61M |
| 5 |
Summit Global Investments
Bountiful,
Utah
|
+$3.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Clal Insurance
Tel-Aviv,
Israel
|
-$42.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$33.4M |
| 3 |
Capricorn Fund Managers
London,
United Kingdom
|
-$10.3M |
| 4 |
Jane Street
New York
|
-$9.08M |
| 5 |
Old Mission Capital
Chicago,
Illinois
|
-$8.3M |
TAK Hedge Fund Activity: Q3 2023 in Review
314 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2023, worth a combined $1.24B — down 5.8% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new TAK positions and 29 closed out — a net gain of 10 holders — while 111 added to existing stakes and 92 trimmed.
The largest buyer was Bank of America, adding an estimated $21M. The largest seller was Clal Insurance, cutting an estimated $42.3M.
- 314 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2023, up from 311 in Q2 2023.
- Funds reported $1.24B of Takeda Pharmaceutical stock for Q3 2023, down 5.8% quarter-over-quarter.
- 39 funds opened new Takeda Pharmaceutical positions in Q3 2023 and 29 closed out, a net change of +10 holders.
- The largest Takeda Pharmaceutical buyer in Q3 2023 was Bank of America, an estimated $21M added.
- The largest Takeda Pharmaceutical seller in Q3 2023 was Clal Insurance, an estimated $42.3M sold.
Based on aggregated 13F filings for Q3 2023.